Eli Lilly News & Latest Eli Lilly Headlines

Shockingly Few Pharma Ads Comply With FDA Guidelines

1:30PM 8/25/2011

Health Care, Pfizer, Eli Lilly, Astrazeneca

Officially, it's the FDA's job to ensure that pharmaceutical ads adhere to guidelines. But the agency's annual compliance budget is $9 million, while drug companies spend $58 billion a year on marketing. So it comes as no surprise that only 18% of ads are in compliance with the rules. But it's still disturbing: This is your health.

The Dark Cloud Over Growing Antidepressant Prescriptions

4:00PM 8/10/2011

By Melly Alazraki

Health Care, Bristol-Myers Squibb, Eli Lilly, Astrazeneca, Consumer Ally

They call it the Great "Recession," but there's no question that these are depressing times. And doctors are writing scripts for antidepressants at an alarming rate -- especially given that many of these doctors aren't psychiatrists. What are the effects on patients who haven't been properly screened?

The 10 Biggest-Selling Drugs That Are About to Lose Their Patent

8:00AM 2/27/2011

By Melly Alazraki

Company News, Investing, Health Care, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Merck, Eli Lilly, Astrazeneca

The pharmaceutical industry is ready to fall off a cliff -- a "patent cliff." Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from drugmakers' bottom lines.

Inside Wall Street: Two Good Reasons for Clinical Data Shares to Soar Again

8:00AM 2/14/2011

By Gene Marcial

Company News, Columns, Investing, Health Care, Pfizer, Stock Picks, Merck, GlaxoSmithKline, Eli Lilly

From October 2010 to February 2011, biotech Clinical Data's stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up -- and making it likely to perhaps double again -- is speculation that a Big Pharma will buy Clinical Data.

The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up

8:00PM 2/09/2011

By Melly Alazraki

Health Care, Genzyme Corporation , GlaxoSmithKline, Novartis, Amgen, Eli Lilly

To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs -- those that address unmet medical needs -- based on fewer trials than usual. But it turns out that many of the pharmaceutical companies fail to conduct follow-up trials to prove the drugs work.

Pfizer Joins Other Pharmas in Giving a Cautious Outlook

3:41PM 2/01/2011

By Melly Alazraki

Company News, Health Care, Earnings, Pfizer, Bristol-Myers Squibb, Novartis, Eli Lilly, Astrazeneca

Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What's ahead for the world's biggest drugmaker:

Another Cancer-Drug Failure Highlights Difficulties Facing Pharmas

12:30PM 1/28/2011

By Melly Alazraki

Company News, Columns, Health Care, Genzyme Corporation , Pfizer, Bristol-Myers Squibb, Sanofi Aventis, Novartis, Eli Lilly, Astrazeneca

Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the patent cliff, when they will be forced to compete with cheaper generics.

As Diabetes Explodes, Big Pharma Is Gearing Up

6:00PM 1/27/2011

By Melly Alazraki

Investing, Health Care, Bristol-Myers Squibb, Sanofi Aventis, Merck, GlaxoSmithKline, Eli Lilly, Astrazeneca

Diabetes is a growing global scourge, but for Big Pharma it's more of a lifesaver -- and many drugmakers are cranking up their research efforts. After all, many existing drugs will soon be losing their patents, and diabetes could be a $55 billion market by 2019.

Merck KGaA Is Latest Pharma to Settle Justice Department Claims

2:00PM 12/21/2010

By Melly Alazraki

Health Care, Pfizer, Merck, GlaxoSmithKline, Abbott, Eli Lilly

German pharmaceutical and chemical company Merck KGaA will pay $280 million to settle a U.S. Department of Justice claim brought against a former subsidiary, Dey Pharma, regarding Medicare and Medicaid reimbursements. This is the fourth such settlement this month alone.

FDA Is Set Decide the Fate of AstraZeneca's Heart Drug Brilinta

9:35AM 12/15/2010

By Melly Alazraki

Company News, Health Care, Bristol-Myers Squibb, Sanofi Aventis, Eli Lilly, Astrazeneca, Stocks in the News

More than a year after AstraZeneca filed for approval, the FDA will make its decision on Thursday. A large study showed the blood thinner worked better than Plavix for treating acute coronary syndrome -- but approval isn't a sure thing, due in part to some oddities in the study's results.